Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
ID: 343381Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/343381

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-243.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) to foster interdisciplinary collaborations aimed at addressing critical biomedical challenges. This funding opportunity encourages the integration of life and physical sciences through multidisciplinary bioengineering approaches to develop innovative technologies and methods in biomedical research, including design-directed and hypothesis-driven studies. The initiative is significant for advancing bioengineering solutions in healthcare, ultimately enhancing patient outcomes through scientific collaboration. Interested applicants, including higher education institutions, nonprofits, and local governments, must submit their proposals by September 7, 2025, and can find more information at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-22-243-Full-Announcement.html
    PAR-22-243.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) program aimed at fostering interdisciplinary collaborations to solve critical biomedical issues. Specifically, the grants encourage multidisciplinary bioengineering approaches that integrate physical and life sciences to develop innovative technologies and methods in biomedical research. Applications may propose diverse research types including design-directed and hypothesis-driven studies. Notably, the FOA will support clinical trials that validate tools or interventions with a focus on translational research, but not traditional phase III clinical trials. The funding opportunity is open to a variety of eligible organizations, including higher education institutions, nonprofits, and local governments, among others. Key submission dates and detailed application instructions are provided, emphasizing adherence to compliance requirements and registrations. The review process evaluates the significance, innovation, approach, and qualifications of the investigators, with an overall impact score reflecting the project's potential influence in the field. This initiative exemplifies NIH’s commitment to advancing bioengineering solutions in healthcare, enhancing patient outcomes through innovative scientific collaboration.
    Similar Opportunities
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.
    Bioengineering Research, Innovation and Technology Education (BRITE) Program (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Bioengineering Research, Innovation and Technology Education (BRITE) Program, a federal grant aimed at fostering the development of undergraduate students in bioengineering and related STEM fields. This program encourages private institutions of higher education to propose integrated educational activities that include a summer bridge program for incoming freshmen, academic year activities, and summer research experiences, ultimately guiding participants toward doctoral degrees or research careers in bioengineering and biomedical imaging. The BRITE Program is crucial for enhancing the capacity for rigorous bioengineering training and addressing the nation's health-related research needs. Interested applicants can contact Dr. Tina Gatlin at gatlincl@nih.gov or by phone at 240-731-3794, with the estimated project start date set for March 1, 2027, and the application window closing on May 11, 2026.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    NIH Research Project Grant (Parent R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIH Research Project Grant, designated as the Parent R01 Clinical Trial Required (Funding Opportunity Number PA-25-305). This grant supports discrete research projects that include at least one clinical trial and align with the scientific missions of participating NIH Institutes and Centers. The initiative aims to foster innovative health-related research and enhance scientific resources, with applications accepted from a diverse range of organizations, including higher education institutions and community-based organizations. Applications will open on January 5, 2025, with subsequent submission deadlines throughout 2025 and 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Trailblazer Award for New and Early-Stage Investigators (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Trailblazer Award aimed at New and Early-Stage Investigators, with a focus on integrating engineering and physical sciences with life and biomedical sciences. This grant opportunity, utilizing the R21 activity code, encourages innovative research projects that may be exploratory, developmental, or high-risk high-impact, and aims to foster collaborations that open new areas of biomedical investigation. Interested applicants, particularly those with expertise in engineering and quantitative sciences, should prepare to submit their applications once the NOFO is officially released, with an estimated synopsis post date of November 21, 2025, and a projected award date of October 1, 2026. For further inquiries, potential applicants can contact Randy King at the National Institute of Biomedical Imaging and Bioengineering via email at Randy.King@nih.gov or by phone at 301-451-0707.
    Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Focused Technology Research and Development (R01 Clinical Trial Not Allowed) grant, aimed at supporting innovative technology projects that advance biomedical research. Eligible applicants include a diverse range of institutions, such as Historically Black Colleges and Universities, Tribal Colleges, and various community-based organizations, with a focus on projects that demonstrate proof-of-concept and the development of working prototypes without integrating clinical trials. This initiative is crucial for fostering technological advancements that enhance understanding of biological processes, with no budget cap and a maximum project duration of five years. Interested applicants can find more information and application guidelines at NIH Grants, with proposals due by January 7, 2028.
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Collaborative Program Grant for Multidisciplinary Teams (RM1), aimed at funding integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to tackle complex biomedical questions. This initiative emphasizes the need for collaborative efforts that demonstrate synergy and diversity, with the goal of achieving significant scientific advancements within the mission of the National Institute of General Medical Sciences (NIGMS). Funding is available for new, renewal, and resubmission applications, with anticipated budgets ranging from $700,000 to $1.5 million per year, and applications must be submitted by January 27, 2026. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.